Aytu BioScience Inc. recently presented clinical findings for its MiOXSYS system at the 32nd annual meeting of the European Society of Human Reproduction and Embryology.
Aytu BioScience is a pharmaceutical company specializing in products for the urology field.
The company specifically created three posters that show the potential of MiOXSYS to help diagnose male infertility. The system is a rapid in vitro diagnostic system for the quantitative measurement of static oxidation-reduction potential (sORP) in human semen.
"The medical and scientific community have long understood that oxidative stress negatively impacts male fertility,” Josh Disbrow, CEO of Aytu BioScience, said. “At the same time, there has not been an easily accessible, rapid, in-office option to measure oxidative stress in semen. Aytu has been committed to conducting research to potentially validate the ability of the MiOXSYS system to fill this gap."
One poster concluded that semen failing at least one parameter for normal semen contained higher amounts of oxidative stress. Another came to similar results and suggested that measuring sORP could give users a measure for confirming sperm morphology. The third poster dealt with Oxidation-reduction Potential (ORP) of Spermatozoa Selected for Intracytoplasmic Sperm Injection (ICSI).